http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 03 Jun 2026 11:58:32 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Downgrades/Craig-Hallum+Downgrades+Cardiff+Oncology+%28CRDF%29+to+Hold/26597528.html <p>Craig-Hallum analyst Albert Lowe downgraded Cardiff Oncology (NASDAQ: CRDF) from Buy to Hold with a price target of $2.00.</p><p>For an analyst ratings summary and ratings history on Cardiff Oncology <a href="http://www.streetinsider.com/rating_history.php?q=CRDF">click here</a>. For more ratings news on Cardiff Oncology <a href="http://www.streetinsider.com/stock_lookup_news.php?q=CRDF&amp;type=analyst">click here</a>.</p><p>Shares of Cardiff Oncology closed at $1.51 yesterday.</p> http://www.streetinsider.com/Downgrades/Craig-Hallum+Downgrades+Cardiff+Oncology+%28CRDF%29+to+Hold/26597528.html Wed, 03 Jun 2026 11:58:32 -0400 CRDF http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Cardiff+Oncology%2C+Inc.++++For%3A+Jun+03/26595975.html si-local-file:///var/storage/secattach/20260603/26595975.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Cardiff+Oncology%2C+Inc.++++For%3A+Jun+03/26595975.html Wed, 03 Jun 2026 08:30:00 -0400 CRDF O.01687800 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Cardiff+Oncology%2C+Inc.++++For%3A+Jun+03/26595975.html si-local-file:///var/storage/secattach/20260603/26595975.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Cardiff+Oncology%2C+Inc.++++For%3A+Jun+03/26595975.html Wed, 03 Jun 2026 08:30:00 -0400 CRDF O.01687800 http://www.streetinsider.com/FDA/Cardiff+Oncology+reports+positive+phase+2+trial+results+for+cancer+drug/26588817.html <p>Cardiff Oncology Inc. (NASDAQ: CRDF) announced positive results from its phase 2 clinical trial evaluating onvansertib in combination with standard chemotherapy for patients with RAS-mutated metastatic colorectal cancer. The data were presented at the American Society of Clinical Oncology Annual Meeting.</p> <p>The trial achieved its primary endpoint with the 30 mg dose of onvansertib combined with FOLFIRI/bevacizumab showing a confirmed objective response rate of 72.2% compared to 42.1% for standard care alone. The median progression-free survival has not been reached in patients receiving the onvansertib combination, while it has been reached in both standard care control arms.</p> <p>The study enrolled patients across http://www.streetinsider.com/FDA/Cardiff+Oncology+reports+positive+phase+2+trial+results+for+cancer+drug/26588817.html Tue, 02 Jun 2026 09:06:16 -0400 A.06822034 A.50216726 CRDF O.01687800 O.20026344 O.21612337 http://www.streetinsider.com/FDA/Cardiff+Oncology+reports+positive+phase+2+trial+results+for+cancer+drug/26588817.html <p>Cardiff Oncology Inc. (NASDAQ: CRDF) announced positive results from its phase 2 clinical trial evaluating onvansertib in combination with standard chemotherapy for patients with RAS-mutated metastatic colorectal cancer. The data were presented at the American Society of Clinical Oncology Annual Meeting.</p> <p>The trial achieved its primary endpoint with the 30 mg dose of onvansertib combined with FOLFIRI/bevacizumab showing a confirmed objective response rate of 72.2% compared to 42.1% for standard care alone. The median progression-free survival has not been reached in patients receiving the onvansertib combination, while it has been reached in both standard care control arms.</p> <p>The study enrolled patients across http://www.streetinsider.com/FDA/Cardiff+Oncology+reports+positive+phase+2+trial+results+for+cancer+drug/26588817.html Tue, 02 Jun 2026 09:06:16 -0400 A.06822034 A.50216726 CRDF O.01687800 O.20026344 O.21612337 http://www.streetinsider.com/FDA/Cardiff+Oncology+reports+positive+phase+2+trial+results+for+cancer+drug/26588817.html <p>Cardiff Oncology Inc. (NASDAQ: CRDF) announced positive results from its phase 2 clinical trial evaluating onvansertib in combination with standard chemotherapy for patients with RAS-mutated metastatic colorectal cancer. The data were presented at the American Society of Clinical Oncology Annual Meeting.</p> <p>The trial achieved its primary endpoint with the 30 mg dose of onvansertib combined with FOLFIRI/bevacizumab showing a confirmed objective response rate of 72.2% compared to 42.1% for standard care alone. The median progression-free survival has not been reached in patients receiving the onvansertib combination, while it has been reached in both standard care control arms.</p> <p>The study enrolled patients across http://www.streetinsider.com/FDA/Cardiff+Oncology+reports+positive+phase+2+trial+results+for+cancer+drug/26588817.html Tue, 02 Jun 2026 09:06:16 -0400 A.06822034 A.50216726 CRDF O.01687800 O.20026344 O.21612337 http://www.streetinsider.com/FDA/Cardiff+Oncology+reports+positive+phase+2+trial+results+for+cancer+drug/26588817.html <p>Cardiff Oncology Inc. (NASDAQ: CRDF) announced positive results from its phase 2 clinical trial evaluating onvansertib in combination with standard chemotherapy for patients with RAS-mutated metastatic colorectal cancer. The data were presented at the American Society of Clinical Oncology Annual Meeting.</p> <p>The trial achieved its primary endpoint with the 30 mg dose of onvansertib combined with FOLFIRI/bevacizumab showing a confirmed objective response rate of 72.2% compared to 42.1% for standard care alone. The median progression-free survival has not been reached in patients receiving the onvansertib combination, while it has been reached in both standard care control arms.</p> <p>The study enrolled patients across http://www.streetinsider.com/FDA/Cardiff+Oncology+reports+positive+phase+2+trial+results+for+cancer+drug/26588817.html Tue, 02 Jun 2026 09:06:16 -0400 A.06822034 A.50216726 CRDF O.01687800 O.20026344 O.21612337 http://www.streetinsider.com/FDA/Cardiff+Oncology+reports+positive+phase+2+trial+results+for+cancer+drug/26588817.html <p>Cardiff Oncology Inc. (NASDAQ: CRDF) announced positive results from its phase 2 clinical trial evaluating onvansertib in combination with standard chemotherapy for patients with RAS-mutated metastatic colorectal cancer. The data were presented at the American Society of Clinical Oncology Annual Meeting.</p> <p>The trial achieved its primary endpoint with the 30 mg dose of onvansertib combined with FOLFIRI/bevacizumab showing a confirmed objective response rate of 72.2% compared to 42.1% for standard care alone. The median progression-free survival has not been reached in patients receiving the onvansertib combination, while it has been reached in both standard care control arms.</p> <p>The study enrolled patients across http://www.streetinsider.com/FDA/Cardiff+Oncology+reports+positive+phase+2+trial+results+for+cancer+drug/26588817.html Tue, 02 Jun 2026 09:06:16 -0400 A.06822034 A.50216726 CRDF O.01687800 O.20026344 O.21612337 http://www.streetinsider.com/FDA/Cardiff+Oncology+reports+positive+phase+2+trial+results+for+cancer+drug/26588817.html <p>Cardiff Oncology Inc. (NASDAQ: CRDF) announced positive results from its phase 2 clinical trial evaluating onvansertib in combination with standard chemotherapy for patients with RAS-mutated metastatic colorectal cancer. The data were presented at the American Society of Clinical Oncology Annual Meeting.</p> <p>The trial achieved its primary endpoint with the 30 mg dose of onvansertib combined with FOLFIRI/bevacizumab showing a confirmed objective response rate of 72.2% compared to 42.1% for standard care alone. The median progression-free survival has not been reached in patients receiving the onvansertib combination, while it has been reached in both standard care control arms.</p> <p>The study enrolled patients across http://www.streetinsider.com/FDA/Cardiff+Oncology+reports+positive+phase+2+trial+results+for+cancer+drug/26588817.html Tue, 02 Jun 2026 09:06:16 -0400 A.06822034 A.50216726 CRDF O.01687800 O.20026344 O.21612337 http://www.streetinsider.com/Press+Releases/Cardiff+Oncology+Announces+Presentation+of+Positive+Results+from+its+Randomized%2C+Controlled+Phase+2+Trial+of+Onvansertib+in+First-Line+RAS-Mutated+mCRC+at+the+2026+ASCO+Annual+Meeting/26588814.html <p align="center"><em>-​ The trial achieved its primary goal of selecting the efficacious and safe dose of onvansertib + standard-of-care (SoC) regimen for the registrational program -​</em></p> <p align="center"><em>-​ 30 mg onvansertib + FOLFIRI/bevacizumab arm showed a dose-dependent improvement in efficacy, including confirmed ORR of 72.2% compared to 42.1% for SoC -​</em></p> <p align="center"><em>-​ Median PFS has not been reached in either 20 or 30 mg onvansertib + FOLFIRI/bevacizumab arm, </em><em>with nine of the 14 patients remaining on treatment in these</em><em> arms -​</em></p> <p align="center"><em>- Onvansertib continues to be safe and well-tolerated with no overlapping or new toxicities http://www.streetinsider.com/Press+Releases/Cardiff+Oncology+Announces+Presentation+of+Positive+Results+from+its+Randomized%2C+Controlled+Phase+2+Trial+of+Onvansertib+in+First-Line+RAS-Mutated+mCRC+at+the+2026+ASCO+Annual+Meeting/26588814.html Tue, 02 Jun 2026 09:06:00 -0400 A.06822034 A.50216726 CRDF O.01687800 O.20026344 O.21612337 http://www.streetinsider.com/Press+Releases/Cardiff+Oncology+Announces+Presentation+of+Positive+Results+from+its+Randomized%2C+Controlled+Phase+2+Trial+of+Onvansertib+in+First-Line+RAS-Mutated+mCRC+at+the+2026+ASCO+Annual+Meeting/26588814.html <p align="center"><em>-​ The trial achieved its primary goal of selecting the efficacious and safe dose of onvansertib + standard-of-care (SoC) regimen for the registrational program -​</em></p> <p align="center"><em>-​ 30 mg onvansertib + FOLFIRI/bevacizumab arm showed a dose-dependent improvement in efficacy, including confirmed ORR of 72.2% compared to 42.1% for SoC -​</em></p> <p align="center"><em>-​ Median PFS has not been reached in either 20 or 30 mg onvansertib + FOLFIRI/bevacizumab arm, </em><em>with nine of the 14 patients remaining on treatment in these</em><em> arms -​</em></p> <p align="center"><em>- Onvansertib continues to be safe and well-tolerated with no overlapping or new toxicities http://www.streetinsider.com/Press+Releases/Cardiff+Oncology+Announces+Presentation+of+Positive+Results+from+its+Randomized%2C+Controlled+Phase+2+Trial+of+Onvansertib+in+First-Line+RAS-Mutated+mCRC+at+the+2026+ASCO+Annual+Meeting/26588814.html Tue, 02 Jun 2026 09:06:00 -0400 A.06822034 A.50216726 CRDF O.01687800 O.20026344 O.21612337 http://www.streetinsider.com/Press+Releases/Cardiff+Oncology+Announces+Presentation+of+Positive+Results+from+its+Randomized%2C+Controlled+Phase+2+Trial+of+Onvansertib+in+First-Line+RAS-Mutated+mCRC+at+the+2026+ASCO+Annual+Meeting/26588814.html <p align="center"><em>-​ The trial achieved its primary goal of selecting the efficacious and safe dose of onvansertib + standard-of-care (SoC) regimen for the registrational program -​</em></p> <p align="center"><em>-​ 30 mg onvansertib + FOLFIRI/bevacizumab arm showed a dose-dependent improvement in efficacy, including confirmed ORR of 72.2% compared to 42.1% for SoC -​</em></p> <p align="center"><em>-​ Median PFS has not been reached in either 20 or 30 mg onvansertib + FOLFIRI/bevacizumab arm, </em><em>with nine of the 14 patients remaining on treatment in these</em><em> arms -​</em></p> <p align="center"><em>- Onvansertib continues to be safe and well-tolerated with no overlapping or new toxicities http://www.streetinsider.com/Press+Releases/Cardiff+Oncology+Announces+Presentation+of+Positive+Results+from+its+Randomized%2C+Controlled+Phase+2+Trial+of+Onvansertib+in+First-Line+RAS-Mutated+mCRC+at+the+2026+ASCO+Annual+Meeting/26588814.html Tue, 02 Jun 2026 09:06:00 -0400 A.06822034 A.50216726 CRDF O.01687800 O.20026344 O.21612337 http://www.streetinsider.com/Press+Releases/Cardiff+Oncology+Announces+Presentation+of+Positive+Results+from+its+Randomized%2C+Controlled+Phase+2+Trial+of+Onvansertib+in+First-Line+RAS-Mutated+mCRC+at+the+2026+ASCO+Annual+Meeting/26588814.html <p align="center"><em>-​ The trial achieved its primary goal of selecting the efficacious and safe dose of onvansertib + standard-of-care (SoC) regimen for the registrational program -​</em></p> <p align="center"><em>-​ 30 mg onvansertib + FOLFIRI/bevacizumab arm showed a dose-dependent improvement in efficacy, including confirmed ORR of 72.2% compared to 42.1% for SoC -​</em></p> <p align="center"><em>-​ Median PFS has not been reached in either 20 or 30 mg onvansertib + FOLFIRI/bevacizumab arm, </em><em>with nine of the 14 patients remaining on treatment in these</em><em> arms -​</em></p> <p align="center"><em>- Onvansertib continues to be safe and well-tolerated with no overlapping or new toxicities http://www.streetinsider.com/Press+Releases/Cardiff+Oncology+Announces+Presentation+of+Positive+Results+from+its+Randomized%2C+Controlled+Phase+2+Trial+of+Onvansertib+in+First-Line+RAS-Mutated+mCRC+at+the+2026+ASCO+Annual+Meeting/26588814.html Tue, 02 Jun 2026 09:06:00 -0400 A.06822034 A.50216726 CRDF O.01687800 O.20026344 O.21612337 http://www.streetinsider.com/Press+Releases/Cardiff+Oncology+Announces+Presentation+of+Positive+Results+from+its+Randomized%2C+Controlled+Phase+2+Trial+of+Onvansertib+in+First-Line+RAS-Mutated+mCRC+at+the+2026+ASCO+Annual+Meeting/26588814.html <p align="center"><em>-​ The trial achieved its primary goal of selecting the efficacious and safe dose of onvansertib + standard-of-care (SoC) regimen for the registrational program -​</em></p> <p align="center"><em>-​ 30 mg onvansertib + FOLFIRI/bevacizumab arm showed a dose-dependent improvement in efficacy, including confirmed ORR of 72.2% compared to 42.1% for SoC -​</em></p> <p align="center"><em>-​ Median PFS has not been reached in either 20 or 30 mg onvansertib + FOLFIRI/bevacizumab arm, </em><em>with nine of the 14 patients remaining on treatment in these</em><em> arms -​</em></p> <p align="center"><em>- Onvansertib continues to be safe and well-tolerated with no overlapping or new toxicities http://www.streetinsider.com/Press+Releases/Cardiff+Oncology+Announces+Presentation+of+Positive+Results+from+its+Randomized%2C+Controlled+Phase+2+Trial+of+Onvansertib+in+First-Line+RAS-Mutated+mCRC+at+the+2026+ASCO+Annual+Meeting/26588814.html Tue, 02 Jun 2026 09:06:00 -0400 A.06822034 A.50216726 CRDF O.01687800 O.20026344 O.21612337 http://www.streetinsider.com/Press+Releases/Cardiff+Oncology+Announces+Presentation+of+Positive+Results+from+its+Randomized%2C+Controlled+Phase+2+Trial+of+Onvansertib+in+First-Line+RAS-Mutated+mCRC+at+the+2026+ASCO+Annual+Meeting/26588814.html <p align="center"><em>-​ The trial achieved its primary goal of selecting the efficacious and safe dose of onvansertib + standard-of-care (SoC) regimen for the registrational program -​</em></p> <p align="center"><em>-​ 30 mg onvansertib + FOLFIRI/bevacizumab arm showed a dose-dependent improvement in efficacy, including confirmed ORR of 72.2% compared to 42.1% for SoC -​</em></p> <p align="center"><em>-​ Median PFS has not been reached in either 20 or 30 mg onvansertib + FOLFIRI/bevacizumab arm, </em><em>with nine of the 14 patients remaining on treatment in these</em><em> arms -​</em></p> <p align="center"><em>- Onvansertib continues to be safe and well-tolerated with no overlapping or new toxicities http://www.streetinsider.com/Press+Releases/Cardiff+Oncology+Announces+Presentation+of+Positive+Results+from+its+Randomized%2C+Controlled+Phase+2+Trial+of+Onvansertib+in+First-Line+RAS-Mutated+mCRC+at+the+2026+ASCO+Annual+Meeting/26588814.html Tue, 02 Jun 2026 09:06:00 -0400 A.06822034 A.50216726 CRDF O.01687800 O.20026344 O.21612337 http://www.streetinsider.com/Globe+Newswire/Cardiff+Oncology+Announces+Presentation+of+Positive+Results+from+its+Randomized%2C+Controlled+Phase+2+Trial+of+Onvansertib+in+First-Line+RAS-Mutated+mCRC+at+the+2026+ASCO+Annual+Meeting/26588814.html <p align="center"><em>-​ The trial achieved its primary goal of selecting the efficacious and safe dose of onvansertib + standard-of-care (SoC) regimen for the registrational program -​</em></p> <p align="center"><em>-​ 30 mg onvansertib + FOLFIRI/bevacizumab arm showed a dose-dependent improvement in efficacy, including confirmed ORR of 72.2% compared to 42.1% for SoC -​</em></p> <p align="center"><em>-​ Median PFS has not been reached in either 20 or 30 mg onvansertib + FOLFIRI/bevacizumab arm, </em><em>with nine of the 14 patients remaining on treatment in these</em><em> arms -​</em></p> <p align="center"><em>- Onvansertib continues to be safe and well-tolerated with no overlapping or new toxicities http://www.streetinsider.com/Globe+Newswire/Cardiff+Oncology+Announces+Presentation+of+Positive+Results+from+its+Randomized%2C+Controlled+Phase+2+Trial+of+Onvansertib+in+First-Line+RAS-Mutated+mCRC+at+the+2026+ASCO+Annual+Meeting/26588814.html Tue, 02 Jun 2026 09:06:00 -0400 A.06822034 A.50216726 CRDF O.01687800 O.20026344 O.21612337 http://www.streetinsider.com/Globe+Newswire/Cardiff+Oncology+Announces+Presentation+of+Positive+Results+from+its+Randomized%2C+Controlled+Phase+2+Trial+of+Onvansertib+in+First-Line+RAS-Mutated+mCRC+at+the+2026+ASCO+Annual+Meeting/26588814.html <p align="center"><em>-​ The trial achieved its primary goal of selecting the efficacious and safe dose of onvansertib + standard-of-care (SoC) regimen for the registrational program -​</em></p> <p align="center"><em>-​ 30 mg onvansertib + FOLFIRI/bevacizumab arm showed a dose-dependent improvement in efficacy, including confirmed ORR of 72.2% compared to 42.1% for SoC -​</em></p> <p align="center"><em>-​ Median PFS has not been reached in either 20 or 30 mg onvansertib + FOLFIRI/bevacizumab arm, </em><em>with nine of the 14 patients remaining on treatment in these</em><em> arms -​</em></p> <p align="center"><em>- Onvansertib continues to be safe and well-tolerated with no overlapping or new toxicities http://www.streetinsider.com/Globe+Newswire/Cardiff+Oncology+Announces+Presentation+of+Positive+Results+from+its+Randomized%2C+Controlled+Phase+2+Trial+of+Onvansertib+in+First-Line+RAS-Mutated+mCRC+at+the+2026+ASCO+Annual+Meeting/26588814.html Tue, 02 Jun 2026 09:06:00 -0400 A.06822034 A.50216726 CRDF O.01687800 O.20026344 O.21612337 http://www.streetinsider.com/Globe+Newswire/Cardiff+Oncology+Announces+Presentation+of+Positive+Results+from+its+Randomized%2C+Controlled+Phase+2+Trial+of+Onvansertib+in+First-Line+RAS-Mutated+mCRC+at+the+2026+ASCO+Annual+Meeting/26588814.html <p align="center"><em>-​ The trial achieved its primary goal of selecting the efficacious and safe dose of onvansertib + standard-of-care (SoC) regimen for the registrational program -​</em></p> <p align="center"><em>-​ 30 mg onvansertib + FOLFIRI/bevacizumab arm showed a dose-dependent improvement in efficacy, including confirmed ORR of 72.2% compared to 42.1% for SoC -​</em></p> <p align="center"><em>-​ Median PFS has not been reached in either 20 or 30 mg onvansertib + FOLFIRI/bevacizumab arm, </em><em>with nine of the 14 patients remaining on treatment in these</em><em> arms -​</em></p> <p align="center"><em>- Onvansertib continues to be safe and well-tolerated with no overlapping or new toxicities http://www.streetinsider.com/Globe+Newswire/Cardiff+Oncology+Announces+Presentation+of+Positive+Results+from+its+Randomized%2C+Controlled+Phase+2+Trial+of+Onvansertib+in+First-Line+RAS-Mutated+mCRC+at+the+2026+ASCO+Annual+Meeting/26588814.html Tue, 02 Jun 2026 09:06:00 -0400 A.06822034 A.50216726 CRDF O.01687800 O.20026344 O.21612337 http://www.streetinsider.com/Globe+Newswire/Cardiff+Oncology+Announces+Presentation+of+Positive+Results+from+its+Randomized%2C+Controlled+Phase+2+Trial+of+Onvansertib+in+First-Line+RAS-Mutated+mCRC+at+the+2026+ASCO+Annual+Meeting/26588814.html <p align="center"><em>-​ The trial achieved its primary goal of selecting the efficacious and safe dose of onvansertib + standard-of-care (SoC) regimen for the registrational program -​</em></p> <p align="center"><em>-​ 30 mg onvansertib + FOLFIRI/bevacizumab arm showed a dose-dependent improvement in efficacy, including confirmed ORR of 72.2% compared to 42.1% for SoC -​</em></p> <p align="center"><em>-​ Median PFS has not been reached in either 20 or 30 mg onvansertib + FOLFIRI/bevacizumab arm, </em><em>with nine of the 14 patients remaining on treatment in these</em><em> arms -​</em></p> <p align="center"><em>- Onvansertib continues to be safe and well-tolerated with no overlapping or new toxicities http://www.streetinsider.com/Globe+Newswire/Cardiff+Oncology+Announces+Presentation+of+Positive+Results+from+its+Randomized%2C+Controlled+Phase+2+Trial+of+Onvansertib+in+First-Line+RAS-Mutated+mCRC+at+the+2026+ASCO+Annual+Meeting/26588814.html Tue, 02 Jun 2026 09:06:00 -0400 A.06822034 A.50216726 CRDF O.01687800 O.20026344 O.21612337 http://www.streetinsider.com/Globe+Newswire/Cardiff+Oncology+Announces+Presentation+of+Positive+Results+from+its+Randomized%2C+Controlled+Phase+2+Trial+of+Onvansertib+in+First-Line+RAS-Mutated+mCRC+at+the+2026+ASCO+Annual+Meeting/26588814.html <p align="center"><em>-​ The trial achieved its primary goal of selecting the efficacious and safe dose of onvansertib + standard-of-care (SoC) regimen for the registrational program -​</em></p> <p align="center"><em>-​ 30 mg onvansertib + FOLFIRI/bevacizumab arm showed a dose-dependent improvement in efficacy, including confirmed ORR of 72.2% compared to 42.1% for SoC -​</em></p> <p align="center"><em>-​ Median PFS has not been reached in either 20 or 30 mg onvansertib + FOLFIRI/bevacizumab arm, </em><em>with nine of the 14 patients remaining on treatment in these</em><em> arms -​</em></p> <p align="center"><em>- Onvansertib continues to be safe and well-tolerated with no overlapping or new toxicities http://www.streetinsider.com/Globe+Newswire/Cardiff+Oncology+Announces+Presentation+of+Positive+Results+from+its+Randomized%2C+Controlled+Phase+2+Trial+of+Onvansertib+in+First-Line+RAS-Mutated+mCRC+at+the+2026+ASCO+Annual+Meeting/26588814.html Tue, 02 Jun 2026 09:06:00 -0400 A.06822034 A.50216726 CRDF O.01687800 O.20026344 O.21612337 http://www.streetinsider.com/Globe+Newswire/Cardiff+Oncology+Announces+Presentation+of+Positive+Results+from+its+Randomized%2C+Controlled+Phase+2+Trial+of+Onvansertib+in+First-Line+RAS-Mutated+mCRC+at+the+2026+ASCO+Annual+Meeting/26588814.html <p align="center"><em>-​ The trial achieved its primary goal of selecting the efficacious and safe dose of onvansertib + standard-of-care (SoC) regimen for the registrational program -​</em></p> <p align="center"><em>-​ 30 mg onvansertib + FOLFIRI/bevacizumab arm showed a dose-dependent improvement in efficacy, including confirmed ORR of 72.2% compared to 42.1% for SoC -​</em></p> <p align="center"><em>-​ Median PFS has not been reached in either 20 or 30 mg onvansertib + FOLFIRI/bevacizumab arm, </em><em>with nine of the 14 patients remaining on treatment in these</em><em> arms -​</em></p> <p align="center"><em>- Onvansertib continues to be safe and well-tolerated with no overlapping or new toxicities http://www.streetinsider.com/Globe+Newswire/Cardiff+Oncology+Announces+Presentation+of+Positive+Results+from+its+Randomized%2C+Controlled+Phase+2+Trial+of+Onvansertib+in+First-Line+RAS-Mutated+mCRC+at+the+2026+ASCO+Annual+Meeting/26588814.html Tue, 02 Jun 2026 09:06:00 -0400 A.06822034 A.50216726 CRDF O.01687800 O.20026344 O.21612337 http://www.streetinsider.com/Press+Releases/Cardiff+Oncology+to+Participate+in+the+Jefferies+Global+Healthcare+Conference/26583304.html <p align="justify">SAN DIEGO, June 01, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will present and participate in 1x1 investor meetings at the Jefferies Global Healthcare Conference on June 2-4, 2026.</p> <p>Details of the presentation can be found below.  </p> <p align="justify"><strong>Format: </strong>Fireside Chat<br/><strong>Presenter:</strong> Mani Mohindru, PhD (President and CEO)   <br/><strong>Date:</strong> 06/04/2026  <br/><strong>Time: </strong>10:30 -11:00 AM ET  <br/>  <br/>Interested parties can register for and access the live webcast for the conference by visiting the “<a target="_blank" href="https://www.globenewswire.com/Tracker?data=wz3xeBu9Q8zG7q16FFxiE8QxMIzyL8XmsG1x96NQqDdy0C96fEhAVci3yYhVqcW1UerOcWwHteU8gUokT7TMm2zXJodmbpmFbztD8fNNbb_hZ7tpV1Ah2H1YdGZSoMls" rel="nofollow" target="_blank">Events</a>” section of the Cardiff Oncology website. http://www.streetinsider.com/Press+Releases/Cardiff+Oncology+to+Participate+in+the+Jefferies+Global+Healthcare+Conference/26583304.html Mon, 01 Jun 2026 16:01:00 -0400 CRDF O.01687800 http://www.streetinsider.com/Press+Releases/Cardiff+Oncology+to+Participate+in+the+Jefferies+Global+Healthcare+Conference/26583304.html <p align="justify">SAN DIEGO, June 01, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will present and participate in 1x1 investor meetings at the Jefferies Global Healthcare Conference on June 2-4, 2026.</p> <p>Details of the presentation can be found below.  </p> <p align="justify"><strong>Format: </strong>Fireside Chat<br/><strong>Presenter:</strong> Mani Mohindru, PhD (President and CEO)   <br/><strong>Date:</strong> 06/04/2026  <br/><strong>Time: </strong>10:30 -11:00 AM ET  <br/>  <br/>Interested parties can register for and access the live webcast for the conference by visiting the “<a target="_blank" href="https://www.globenewswire.com/Tracker?data=wz3xeBu9Q8zG7q16FFxiE8QxMIzyL8XmsG1x96NQqDdy0C96fEhAVci3yYhVqcW1UerOcWwHteU8gUokT7TMm2zXJodmbpmFbztD8fNNbb_hZ7tpV1Ah2H1YdGZSoMls" rel="nofollow" target="_blank">Events</a>” section of the Cardiff Oncology website. http://www.streetinsider.com/Press+Releases/Cardiff+Oncology+to+Participate+in+the+Jefferies+Global+Healthcare+Conference/26583304.html Mon, 01 Jun 2026 16:01:00 -0400 CRDF O.01687800 http://www.streetinsider.com/Globe+Newswire/Cardiff+Oncology+to+Participate+in+the+Jefferies+Global+Healthcare+Conference/26583304.html <p align="justify">SAN DIEGO, June 01, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will present and participate in 1x1 investor meetings at the Jefferies Global Healthcare Conference on June 2-4, 2026.</p> <p>Details of the presentation can be found below.  </p> <p align="justify"><strong>Format: </strong>Fireside Chat<br/><strong>Presenter:</strong> Mani Mohindru, PhD (President and CEO)   <br/><strong>Date:</strong> 06/04/2026  <br/><strong>Time: </strong>10:30 -11:00 AM ET  <br/>  <br/>Interested parties can register for and access the live webcast for the conference by visiting the “<a target="_blank" href="https://www.globenewswire.com/Tracker?data=wz3xeBu9Q8zG7q16FFxiE8QxMIzyL8XmsG1x96NQqDdy0C96fEhAVci3yYhVqcW1UerOcWwHteU8gUokT7TMm2zXJodmbpmFbztD8fNNbb_hZ7tpV1Ah2H1YdGZSoMls" rel="nofollow" target="_blank">Events</a>” section of the Cardiff Oncology website. http://www.streetinsider.com/Globe+Newswire/Cardiff+Oncology+to+Participate+in+the+Jefferies+Global+Healthcare+Conference/26583304.html Mon, 01 Jun 2026 16:01:00 -0400 CRDF O.01687800 http://www.streetinsider.com/Globe+Newswire/Cardiff+Oncology+to+Participate+in+the+Jefferies+Global+Healthcare+Conference/26583304.html <p align="justify">SAN DIEGO, June 01, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will present and participate in 1x1 investor meetings at the Jefferies Global Healthcare Conference on June 2-4, 2026.</p> <p>Details of the presentation can be found below.  </p> <p align="justify"><strong>Format: </strong>Fireside Chat<br/><strong>Presenter:</strong> Mani Mohindru, PhD (President and CEO)   <br/><strong>Date:</strong> 06/04/2026  <br/><strong>Time: </strong>10:30 -11:00 AM ET  <br/>  <br/>Interested parties can register for and access the live webcast for the conference by visiting the “<a target="_blank" href="https://www.globenewswire.com/Tracker?data=wz3xeBu9Q8zG7q16FFxiE8QxMIzyL8XmsG1x96NQqDdy0C96fEhAVci3yYhVqcW1UerOcWwHteU8gUokT7TMm2zXJodmbpmFbztD8fNNbb_hZ7tpV1Ah2H1YdGZSoMls" rel="nofollow" target="_blank">Events</a>” section of the Cardiff Oncology website. http://www.streetinsider.com/Globe+Newswire/Cardiff+Oncology+to+Participate+in+the+Jefferies+Global+Healthcare+Conference/26583304.html Mon, 01 Jun 2026 16:01:00 -0400 CRDF O.01687800